<DOC>
	<DOC>NCT02229773</DOC>
	<brief_summary>Lipid lowering effect, investigation of pharmacodynamics (inhibition of oxidosqualene cyclase, monoepoxysqualene (MES) as marker), safety / tolerability and preliminary pharmacokinetics</brief_summary>
	<brief_title>Pharmacodynamics, Preliminary Pharmacokinetics and Tolerability of BIBB 1464 (Tablet) in Hyperlipemic Healthy Male Subjects</brief_title>
	<detailed_description />
	<mesh_term>Pravastatin</mesh_term>
	<criteria>Healthy male Caucasian subjects as determined by results of screening Written informed consent in accordance with GCP and local legislation given Age &gt;= 18 and &lt;= 65 years Broca &gt;= 20% and &lt;= + 30% LDLcholesterol level &gt;= 3.3 mmol/L at prescreening and at the two screening visits Any finding of the medical examination. (including blood pressure, pulse rate and ECG) deviating from normal and of clinical relevance Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal (including thyroid) disorder Surgery of the gastrointestinal tract (except appendectomy) Disease of the central nervous system (such as epilepsy) or psychiatric disorders or neurological disorders History or orthostatic hypotension, fainting spells or blackouts Chronic or relevant acute infections History of allergy/hypersensitivity (including drug allergy) which is deemed relevant to the trial as judged the investigator Intake of drugs with a long halflife (&gt; 24 hours) (&lt;= 1 month prior to administration or during the trial) Use of any drugs which might influence the result of the trial (&lt;= 10 days prior to administration or during the trial) Participation in another trial with an investigational drug (&lt;= 2 month prior to administration or during the trial) Smoker (&gt; 10 cigarettes or &gt; 3 cigars or &gt;3 pipes/day) Inability to refrain from smoking during the period of the study Alcohol abuse (&gt;60/g/day) Drug abuse Blood donation (&gt;400ml &lt;=1 month prior to administration) Excessive physical activities (&lt;=5 days prior to administration) Any laboratory value outside the normal range of clinical relevance LDL cholesterol screening measurements day 1 and day 7 the different between these two values exceed 12% of the higher dose subjects who are vegetarian Eyelens Cataract extraction in one or both eyes deemed likely within 2 years ("senile", nonidiopathic will not automatically exclude patients from participation) Lens Opacities Classification System (LOCS) III grade &gt;3.0 (for nuclear opalescence or cortical grad) &gt;0.5 (for posterior sub capsular grad) Log MAR BaileyLovie visual acuity &gt;0.5 Corneal or conjunctival problems which would preclude lens photography Shallow anterior chamber with risk of angleclosure glaucoma Pupil will not dilate to at least 6 mm Visually significant fundus pathology in clinician's judgment Amblyopia, optic nerve disease, iritis, history of eye surgery, argon or YAG laser, major eye trauma, extended use (daily for &gt;3 month) of ocular or systemic corticosteroid treatment , use of anticoagulants, or glaucoma therapy, or participation in another clinical trial investigation an anticataract or cataractogenic formulation within the last year</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2014</verification_date>
</DOC>